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Background. Using our statin analysis method, it was possible to uncover a signiﬁcant drop in statin levels (atorvastatin, simvas-
tatin, and metabolites) after extracorporeal LDL-cholesterol elimination (EE) in severe familial hypercholesterolemia (FH). The
purposeofthisworkwastoidentifythemechanismunderlyingthisdropanditsclinicalsigniﬁcanceaswellastoproposemeasures
to optimize a pharmacotherapeutical regimen that can prevent the loss of statins. Methods. Ultra High Performance Liquid
Chromatography (UHPLC) connected to the triple quadrupole MS/MS system was used. Patients. A group of long-term treated
patients (3–12 years of treatment) with severe FH (12 patients) and treated regularly by LDL-apheresis (immunoadsorption) or
haemorheopheresis (cascade ﬁltration) were included in this study. Results. After EE, the level of statins and their metabolites
decreased (atorvastatin before/after LDL-apheresis: 8.83/3.46nmol/l; before/after haemorheopheresis: 37.02/18.94nmol/l). A
speciﬁc loss was found (concentration of atorvastatin for LDL-apheresis/haemorheopheresis: 0.28/3.04nmol/l in washing ﬂuids;
11.07nmol/l in ﬁlters). To prevent substantial loss of statin concentrations, a pharmacotherapeutic regimen with a longer time
interval between the dose of statins and EE is recommended (15 hours). Conclusions. A speciﬁc loss of statins was found in
adsorbent columns and ﬁlters. The decrease can be prevented by the suggested dosage scheme.
1.Introduction
Familialhypercholesterolemia(FH)isaseveremetabolicdis-
order that leads to accelerated atheromatosis [1]. A complete
changeinlifestyle,astrictdiet,andintensivecombinedphar-
macotherapy are necessary in patients with FH and provide
very good results in most patients [2]. In spite of these
measures to resolve FH, extracorporeal elimination (EE)
of low-density lipoprotein cholesterol (LDL-cholesterol) is
still necessary for patients who are homozygous for the
disease-causing gene and a small number of heterozygous
patients. EE is carried out using currently accepted methods,
including heparin-induced extracorporeal LDL precipitation
(HELP), direct adsorption of lipoprotein (DALI), LDL-
apheresis (immunoadsorption), dextran-sulfate adsorption
(lipopheresis), and hemorheopheresis (cascade ﬁltration)
[3–6]. Statins, combined with other cholesterol-lowering
agents (ezetimibe, ﬁbrates, or bile acid sequestrants), are
the most eﬃcient and the most widely used pharmacother-
apeutics for FH treatment [7–9]. The therapeutic range of
statinsisrelativelylow(typically10–80mg/day)[10,11],and
patients with severe FH must take the maximally tolerable
dose of statins. Such doses have a potent cholesterol-
lowering eﬀect and signiﬁcantly reduce the morbidity and
mortality associated with coronary heart disease, as shown
by many clinical trials [9, 12–14]. However, some statins2 Journal of Biomedicine and Biotechnology
exhibit a number of adverse eﬀects, such as myopathy
or rhabdomyolysis [1, 15–18]. Nevertheless, therapeutic
drug monitoring is not routinely carried out for patients
treated with statins. Patients are only advised to report the
development of muscle aches, pains, or weakness, which
increases the risk of clinically important adverse eﬀects. The
determination of statin levels in biological ﬂuids is clinically
important, but measurements are technically diﬃcult and
quite expensive; therefore, statin levels cannot be routinely
determined in a common biochemical laboratory. Such
determinationrequiresspecializedlaboratoryprocessingand
analytical equipment; many important and interesting data
were described elsewhere [19–22].
A sensitive and selective analytical method for statin
analysis during EE was developed in our laboratories. After
the initial analyses, we observed considerable decreases in
statin levels after EE in some patients. This decrease could
adversely inﬂuence our patients, although no data were
found in the literature to allow us to evaluate the possible
eﬀects of this decrease. The aims of the present work were
to evaluate the quantity of statin loss (as well as active
metabolites of statins) during EE, to identify the mechanism
of statin loss during EE (possibly captured also in absorbers
or ﬁlters), and to propose measures to reduce losses, such as
adjustments to the pharmacotherapeutical regimen.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Working standards of simvas-
tatin were obtained from Sigma Aldrich (Prague, Czech
Republic). Working standards of simvastatin acid, ator-
vastatin lactone and atorvastatin, p-hydroxyatorvastatin,
o-hydroxyatorvastatin, deuterium-labeled simvastatin (D6-
methyl groups), and deuterium-labeled atorvastatin (D5-
phenyl ring) were purchased from Toronto Research Chemi-
cals (Ontario, Canada).
Acetic acid (reagent grade), ammonium (reagent grade),
and acetonitrile (LC-MS grade) were purchased from Sigma
Aldrich. High-performance liquid chromatography (HPLC)
grade water was obtained with a Milli-Q reverse osmosis
Millipore (Bedford, MA, USA) and met the requirements of
the European Pharmacopoeia.
2.2. Therapeutic Procedures. All patients treated in the long
term with EE in the Czech Republic were chosen for the
purpose of this study. The following two EE approaches were
used in twelve patients.
2.2.1. LDL-Apheresis. The patients were treated by LDL-
apheresis based on the principle of immunoadsorption.
The procedure consisted of the following two main steps:
(1) separation of plasma using a Cobe-Spectra continual
centrifugation separator (Cobe, Denver, USA) followed by
(2) passage of plasma through a pair of Lipopak 400
adsorbers (Pocard, Moscow, Russia) with sheep antibodies
against apolipoprotein B. The adsorbers are placed into an
automatic adsorption-desorption device (Adasorb, Medicap,
Ulrichstein, SRN). The pair of columns was alternated
until the cholesterol level was signiﬁcantly below the limit.
The target LDL-cholesterol value used at the start of this
research was less than 1mmol/L, but the procedure has
become much more eﬀective, with a target value decreased
to below 0.5mmol/L (normal values typically range from 1.5
to 3.36mmol/L).
2.2.2. Hemorheopheresis (Cascade Filtration). Cell-free plas-
ma was obtained by high-speed centrifugation using a
Cobe-Spectra separator, as described above. The plasma
was then pumped through the second level (ﬁlters). Based
on their properties, Evaﬂux 4A and 5A (Kuraray) ﬁlters
were used in our modiﬁcation of cascade ﬁltration (named
“hemorheopheresis” in our paper). The ﬁlters contained
hollow ﬁbers made from ethylene-vinyl alcohol material
w i t hap o r es i z eo f0 . 0 3o r0 . 0 4 µm. Anticoagulation was
performed with ACD-A (Baxter, Munich, Germany) and an
initial intravenous bolus injection of4000 IUofheparin. The
body plasma volume was calculated using the Cobe-Spectra
separator computer, and we washed 1.5X of the body plasma
volume.
2.2.3. Monitored Parameters. To monitor the safety, eﬃ-
ciency,andcost-eﬀectivenessofthetherapy,thepatientswere
regularly tested for a set of basic hematological, biochemical,
and immunological parameters (data not shown) [23–26].
This study was approved by the institutional ethics
committee, and all examinations were in agreement with
the principles of the currently valid version of the Helsinki
declaration. All patients signed an informed consent form.
2.3. Chromatography and Mass Spectrometry. The previ-
ously developed and validated ultra-high-performance liq-
uid chromatography tandem mass spectrometry (UHPLC-
MS/MS) technique was applied to measure the levels of
simvastatin, atorvastatin, and their metabolites in serum and
washing liquids [27]. A UHPLC system (Waters, Prague,
Czech Republic) was used for the purposes of this study,
and the system consisted of an ACQ-binary solvent manager
and an ACQ-sample manager. An MS/MS triple quadrupole
system was also used for the purposes of this study. A
Quattro Micro apparatus (Micromass, Manchester, GB)
was equipped with a multimode ionization source (ESCI).
Following SRM (selected reaction monitoring) transitions
were monitored: atorvastatin (559 > 440 and 559 > 466), and
atorvastatin D5 (564 > 445), p-hydroxyatorvastatin (575 >
440 and 575 > 466), o-hydroxyatorvastatin (575 > 440 and
575 > 466), atorvastatin lactone (541 > 448 and 541 > 422).
2.4. Preparation of Standard Solutions and Samples. The
standard stock solutions used to measure statin levels were
prepared according to the procedure described in [27]. Stock
solutions were further diluted by the mobile phase (for
stability reasons, the pH of the solution was maintained
between 4.0 and 5.0 to prevent interconversion). Serum
samples were prepared using solid phase extraction (SPE)
with a Discovery DSC-18 SPE support (SPE procedure I). An
internal standard (100µL) was added to 900µL of the serumJournal of Biomedicine and Biotechnology 3
samples containing the analytes. The mixture was loaded
onto a Discovery DSC-18 sorbent previously activated with
1mL of acetonitrile and conditioned with 1mL of 0.1M
ammonium acetate buﬀer, pH 4.5. An SPE cartridge with
a loaded sample was washed two times with 1mL of 0.1M
ammonium acetate, pH 4.5, then once with 1mL of a
mixture of acetonitrile [0.01M ammonium acetate buﬀer,
pH 4.5 (15:85, v/v)]. Finally, the analytes were eluted with
1mLofacetonitrile[0.1Mammoniumacetatebuﬀer,pH4.5
(95:5, v/v)]. The eluate was ﬁltered through a 0.20µmP T F E
ﬁlter, and the sample was injected onto the UHPLC system
[27].
The samples of washing liquids were prepared using
a modiﬁed version of SPE procedure I. Four cycles were
usually used during LDL-apheresis. First, the plasma of the
patient was administered through the adsorbent columns
to bind cholesterol. Subsequently, in the washing step,
cholesterol was washed away by glycine acidiﬁcation. In
this phase, statins potentially retained in the adsorbent
columns might be released as well. Therefore, the glycine
washing solution was also analyzed by UHPLC-MS/MS.
The sample was obtained during the ﬁrst cycle, when the
highest amount of cholesterol was present in the plasma.
During the hemorheopheresis procedure, all washing liquid
was collected in the waste bag and examined by UHPLC-
MS/MS. A homogenization step was necessary to obtain
representative samples of washing liquids. Therefore, waste
bags were shaken for 30 minutes. Prior to the extraction of
washing liquids, the samples were centrifuged at 3000 × g
for 10 minutes. If necessary, the samples were also ﬁltered
through a 0.20µm PTFE ﬁlter. For SPE, 5mL of supernatant
was used. Conditioning, washing, and elution steps were
performed according to SPE procedure I.
Preparation of samples from ﬁlters was performed
as follows. After the ﬁltering procedure, all liquids were
removed from the ﬁlters. The ﬁlters were then washed in
acetonitrile to remove any remaining statins. All liquid was
homogenized by shaking. Subsequently, the samples were
centrifuged at 3000 × g for 10 minutes prior to extraction of
the washed ﬁlters. If necessary, the samples were also ﬁltered
through 0.20µm PTFE ﬁlters. For SPE, 5mL of supernatant
was used. Conditioning, washing, and elution steps were
performedaccordingtoSPEprocedureI.However,itwasnot
possible to conduct this experiment quantitatively because
some amount of liquid always remained in the ﬁlters, so the
measurements were only an approximate value.
2.5. Patients. The patient pool included all long-term treated
patients undergoing EE procedures in the Czech Republic.
This set of 12 patients was gradually generated after 1996.
The patients were treated for 3–12 years (average: 7.2 ±
2.96 years, range: 2–11.5, median: 7.25). The group of 12
patients consisted of 7 men and 5 women. The average age
of the patients was 47 ± 16.6 years (range: 21–63, median:
52 years). The clinical phenotype of FH was characterized
by an increased level of total plasmatic cholesterol and LDL-
c h o l e s t e r o la sw e l la sb yt h eo c c u r r e n c eo fx a n t h o m a sa n d
premature symptoms of ischemic heart disease. The MedPed
criteria [28], using thresholds for total cholesterol and LDL
c h o l e s t e r o ll e v e l sa b o v et h e9 5 t hp e r c e n t i l es p e c i ﬁ ct ot h e
Czech population [29], and the individual’s age and family
history were applied. Furthermore, DNA-based evidence of
a mutation in the low-density lipoprotein receptor (LDLR)
gene was used as the criterion for homozygous FH. None
of the patients carried a mutation in the apolipoprotein B
(APOB) gene.
All patients were treated with high-dose statins (40mg
simvastatin or 40–80mg atorvastatin daily). One patient
was treated with combined fenoﬁbrate (200mg daily) and a
statin, two patients were treated with combined biliary acid-
binding resins (6g daily) and a statin, and 10 patients were
treated with combined Ezetrol (ezetimibe, 10mg daily) and
astatin.RosuvastatinwasnotavailableintheCzechRepublic
during the study period.
EE procedures were performed regularly, with three
homozygous FH patients receiving EE every 10–14 days and
other hypercholesterolemic patients receiving EE every 3-4
weeks. Five patients presented an increased level of lipopro-
tein (a) (>0.30nmol/L), with an average level of 1.20 ±
0.84nmol/L (range: 0.40–2.42nmol/L, median: 1.1nmol/L).
The average body mass index was 26.99 ± 6.2 (range:
18.7–42.6, median: 26.35). Nine patients suﬀered from
hypercholesterolemia of Fredrickson phenotype IIa. These
patients were either genetically conﬁrmed as homozygous
patients with a defective LDLR gene or heterozygous FH
patients. Three patients displayed abnormally high levels of
cholesterol and triglycerides. Two patients had a phenotype
consistent with Fredrickson IIb. One patient, who was
simultaneously treated for type II diabetes mellitus, had a
phenotype consistent with Fredrickson IIb-IV.
2.6. Statistical Evaluation. The signiﬁcance of diﬀerences
before and after extracorporeal therapy was examined by
the Mann-Whitney U test, using the NCSS 2004 statistical
software (Number Cruncher Statistical Systems, Kaysville,
USA). Diﬀerences were considered signiﬁcant for P ≤ 0.05.
3. Results
Lipoprotein levels were relatively stable in all patients at the
time of examination. The ﬁnal measurements showed the
average total cholesterol to be 7.49 ± 1.61nmol/L, LDL-
cholesterol to be 5.2 ± 1.39nmol/L, and HDL-cholesterol to
be 1.56 ± 0.43nmol/L.
3.1.PreliminaryExperiments. First,preliminaryexperiments
were performed to verify the applicability of the UHPLC-
MS/MS method in determining the inﬂuence of EE proce-
duresonstatinconcentrationsinbiologicalﬂuids.Intotal,36
samples were analyzed (before and after the EE procedure),
including three samples taken from each of twelve patients
at regular intervals. Eleven patients were treated with ator-
vastatin and one with simvastatin during the preliminary
study. From the preliminary results, it was evident that
intraindividual variability among the particular analyses was
low. Therefore, the method was found to be convenient
and reliable. The UHPLC-MS/MS method validation was4 Journal of Biomedicine and Biotechnology
performed according to the International Conference on
Harmonization (ICH) guidelines for validation [29].
3.2. Detailed Study. Plasma statin concentrations were mea-
sured regularly over the course of the study. In total, 170
samples (85 pairs, collected twice from each patient during
2009) were analyzed in all patients when they attended the
procedures. For each patient, samples were always analyzed
in pairs for concentrations of statins and their metabolites,
with one sample taken before the procedure and the other
sample taken after the procedure. Only eleven of the twelve
patients were admitted to this study because one patient,
whowastreatedwithsimvastatin,hadpreviouslyswitchedto
rosuvastatin therapy when it became available in the Czech
Republic. In the following study, only patients treated by
atorvastatin were observed.
The results from the study are shown in Table 1.A f t e r
the EE procedures, clinically signiﬁcant reductions of statins
and their metabolites were observed. The concentration
of atorvastatin in the serum decreased by an average of
47.2%, p-OH-atorvastatin by 50.0%, o-OH-atorvastatin by
37.9%, and atorvastatin lactone by 49.1%. The changes
in concentrations of statins and their metabolites were
evaluated statistically using the Wilcoxon nonparametric t-
test. The diﬀerence in mean concentration before and after
the procedures was signiﬁcant for the patients as a group
(see Table 1). However, the two EE procedures diﬀer; LDL-
apheresis is an APOB-speciﬁc treatment, and hemorheo-
pheresis is a nonspeciﬁc ﬁltration procedure. Therefore,
it was necessary to evaluate the results separately. Upon
individual evaluation of each EE procedure, we found that
the statin and metabolite levels diﬀered signiﬁcantly before
and after LDL-apheresis (Table 1). Results obtained for
the hemorheopheresis group were also signiﬁcant, except
those for one metabolite (p-OH-atorvastatin). During LDL-
apheresis, the atorvastatin serum concentration decreased
by 60.8%, pOH-atorvastatin by 59.0%, o-OH-atorvastatin
by 44.5%, and atorvastatin lactone by 58.9%. During
hemorheopheresis, the atorvastatin serum concentration
decreased by 48.8%, p-OH-atorvastatin by 43.60%, o-OH-
atorvastatin by 44.0%, and atorvastatin lactone by 41.6%.
3.3. The Mechanism of the Statin Drop. Considering the
relatively large decrease of serum statin concentrations in
all patients studied, further experiments were performed to
test the hypothesis that adsorbent columns retain statins
during LDL-apheresis and that ﬁlters retain statins during
hemorheopheresis. To test this hypothesis, 25 samples were
collected and subjected to UHPLC-MS/MS analysis. In
addition, 22 samples of waste liquids were examined to
evaluate each patient twice. The results of this experiment
are presented in Table 2. The average concentrations of
statins in washing liquids were substantially lower than the
serum levels (the atorvastatin concentration during LDL-
apheresis was 0.28 ± 0.20nmol/L, during hemorheopheresis
was 3.04 ± 3.58 nmol/L, and for all patients was 1.34 ±
2.51nmol/L). An analysis of LDL-apheresis was performed
onthetotalamountofwasteliquid;however,thewasteliquid
wasonlyobtainedfromtheﬁrstcycle(about900mL),during
which the cholesterol retained in the adsorbent column was
washed out with glycine. As stated above, both adsorbent
columns worked together as a pair, and each column was
typically ﬁlled and washed out four times. In total, 3600mL
of glycine was used, so measurements from all cycles were
not technically possible. However, statins are considered to
be present in the highest amounts in washing liquids during
the ﬁrst cycle. In contrast, during hemorheopheresis, it was
possible to analyze all of the washing liquid (500–1500mL
of liquid contained in a bag). The volume of washing
liquid during hemorheopheresis varied, depending on the
number of times the Evaﬂux ﬁlter was washed, which was
controlled by pressure feed-back. If the pressure increased
above safe limits, the ﬁlter would wash back into the waste
bag. The number of washing cycles depended mainly on the
ﬁbrinogen level of the patient.
The measurements for the ﬁlter matrix (three sam-
ples) revealed substantial retention of statins as well.
From the matrix, the median atorvastatin level in the
eluate was 7.83nmol/L, the median p-OH-atorvastatin level
was 1.20nmol/L, the median o-OH-atorvastatin level was
7.71nmol/L, and the median atorvastatin-lactone level was
3.83nmol/L(Table3).Themeasurementsfortheeluatefrom
the ﬁlter matrix were performed in triplicate only, due to
technical diﬃculties and economic demands.
Thecorrelationbetweenthechangesofstatinlevels(ator-
vastatin, p-OH-atorvastatin, o-OH atorvastatin, and ator-
vastatin lactone) and changes of both the total cholesterol
levels and LDL-cholesterol levels in the group of patients
taking the statins 2–4 or 15 hours before the procedures was
tested using Pearson’s coeﬃcient, and the same analysis was
used to examine relative correlation (software STATISTICA
8). No signiﬁcant correlation was found (P>0.05).
4. Discussion
Advances in biotechnology bring new knowledge and new
methodsthatcanbeusedinmanybranchesofmedicine[30–
34]. One such advance is extracorporeal therapy, which can
be either non-speciﬁc (such as plasma exchange) or speciﬁc
(such as immunoadsorption). This type of procedure can
constitute an important and sometimes decisive component
of FH therapy. EE with regard to medical, technical, and
economic demands is indicated in cases when classical
methods fail.
Our study revealed a signiﬁcant decrease in atorvastatin
and simvastatin levels after EE using LDL-apheresis and
hemorheopheresis. The decrease was observed for the parent
compound as well as for the metabolites (except for p-
OH-atorvastatin in the hemorheopheresis group) and the
interconversion products. After EE, the concentrations were
about half of the initial concentrations. The question of
clinical importance of statin level ﬂuctuation after EE is
very interesting. The notion that EE reduces plasma levels
of statins is, at face value, an important issue. However, in
reality the low bioavailability of statins and the fact that their
LDL-lowering eﬃcacy is not correlated with area under the
c u r v ec o n c e n t r a t i o n sf r o m0t o2 4h o u r sa f t e rd o s i n g[ 35]Journal of Biomedicine and Biotechnology 5
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Table 2: Atorvastatin and its metabolites in waste ﬂuids.
Samples from the
procedure
Compound Number of samples Average (nmol/L) Standard deviation Median (nmol/L) (range)
LDL-apheresis
AT 15 0.28 0.20 0.22 (0.00–0.77)
p-OH-AT 15 0.07 0.07 0.06 (0.00–0.25)
o-OH-AT 15 0.09 0.11 0.06 (0.00–0.39)
ATL 15 0.15 0.18 0.12 (0.00–0.74)
Hemorheopheresis
AT 7 3.04 3.58 2.57 (0.21–12.05)
p-OH-AT 7 0.37 0.37 0.29 (0.00–1.06)
o-OH-AT 7 1.72 1.33 1.38 (0.05– 4.11)
ATL 7 2.52 1.85 2.23 (0.96–6.38)
Both procedures
(Hemorheopheresis
+LDL-apheresis)
AT 22 1.34 2.51 0.34 (0.00–12.05)
p-OH-AT 22 0.19 0.27 0.08 (0.00–1.06)
o-OH-AT 22 0.71 1.13 0.12 (0.00–4.11)
ATL 22 0.91 1.51 0.18 (0.00–6.38)
p-OH-AT: p-hydroxyatorvastatin, o-OH-AT: o-hydroxyatorvastatin, AT: atorvastatin, ATL: atorvastatin lactone.
Table 3: Atorvastatin and its metabolites in the matrix ﬁlter.
Compound Number of samples Average (nmol/L) Standard deviation (SD) Median (nmol/L) (range)
AT 3 11.07 12.32 7.83 (0.70–24.69)
p-OH-AT 3 1.18 0.98 1.20 (0.19–2.15)
o-OH-AT 3 8.28 8.25 7.71 (0.33–16.80)
ATL 3 6.32 7.51 3.83 (0.38–14.76)
p-OH-AT: p-hydroxyatorvastatin, o-OH-AT: o-hydroxyatorvastatin, AT: atorvastatin, ATL: atorvastatin lactone.
suggest that reducing plasma levels of statins by apheresis
would not adversely aﬀect plasma LDL levels. Also in our
study the correlation was not found between statin levels
and their LDL-lowering eﬀect. But other data indicate that
high plasma levels of statins are associated with myotoxicity,
which implies that lowering statin levels with lipoprotein
apheresis might be useful in that context. There are also data
indicating that the eﬀect of statins is not only hypolipidemic,
but pleiotropic [36]. Statin dose/level lowering is in relation
to the many unwanted pathophysiological mechanisms, such
as in coronary heart disease complications [37], beginning
of arrhythmias [38] statins can also inﬂuence some renal
disorders [39] and play an important role in endothelial or
enzymatic cascade activities inclusive of pathological chain
“inﬂammation—thrombocyte activation—thrombogenesis”
[40]. It can be concluded that maximum tolerated doses of
statins and corresponding high and stable statin levels are
desirable in patients with severe FH.
Statins and their metabolites, which may also be eﬀective
in lowering cholesterol levels (e.g., atorvastatin hydroxy-
metabolites), bind to blood proteins, and several of these
statincarrierscanalsobeeliminatedduringanEEprocedure.
The levels of statins in biological ﬂuids are very low
because statins have a high ﬁrst-pass metabolism. Following
dosing with conventional statins widely used in therapy
(atorvastatin, simvastatin, and lovastatin), only about 5%
of the dosed statin reaches the systemic circulation. Typical
plasma concentrations of statins are ng/mL levels. The
concentrations of therapeutically eﬀective metabolites of
atorvastatin are even lower, typically 0.1–20ng/mL [41, 42].
The diﬀerences in the statin decrease between LDL-
apheresis and hemorheopheresis are likely related to the
diﬀerent treatment approaches and the duration of the
procedures. Similarly, the concentrations of statins before
the procedure were higher in the hemorheopheresis group.
Patients treated by hemorheopheresis took atorvastatin in
the morning, followed by EE within 2–4 hours. Atorvas-
tatin is quickly absorbed after oral administration, and a
maximum plasmatic concentration is reached within 1-2
hours [41]. Therefore, the samples from these patients were
taken shortly after the maximum plasmatic concentration
of statins was reached. Patients treated by LDL-apheresis
took the statin dose the evening before EE, so the sam-
ples were obtained approximately 15 hours after dosing,
which is longer than the mean elimination half-life of 14
hours [41, 42]. Only one patient treated by LDL-apheresis
took the statin dose in the morning, which, in his daily
regimen, meant at 4 A.M. For this patient, LDL-apheresis
was performed within 5-6 hours of dosing. Therefore,
the atorvastatin concentration before EE was found to
be substantially higher in this patient (average of three
measurements=13.65nmol/L)ascomparedwiththeaverage
of all patients treated by LDL-apheresis (8.83nmol/L).
However, the atorvastatin concentration before EE was lower
in this patient than in patients treated by hemorheopheresis
(37.02nmol/L). The time interval between dosage and EEJournal of Biomedicine and Biotechnology 7
dramatically impacted the measurements of statin concen-
trations. Similarly, the duration of EE also aﬀected the statin
concentrations. The time interval between the two blood
collections for the determination of statin concentration
before and after EE was 3-4 hours in the hemorheopheresis
group and 5-6 hours in the LDL-apheresis group.
The pharmacokinetic properties of statins are well
knownunderstandardconditions.Ourﬁndingoftheimpor-
tanceoftimeintervalbetweenbloodwithdrawals(beforeand
after EE) on the reduction of statin concentrations could
be based on pharmacokinetics, unless the metabolism of
statins diﬀers between EE procedures. It would be possible
to determine whether the time period is unimportant or
decisive or if it is the only factor inﬂuencing the decrease
ofstatinconcentration.Unfortunately,noinformationabout
changesinmetabolismduringEEwasfoundintheliterature.
However,itmaybeconsideredthattheEEprocedureisatype
ofstressfulsituation,whichmaychangethepharmacokinetic
decrease of statin concentrations over time. Therefore, a
more precise evaluation of measurements of washing liquids
and ﬁlters was undertaken in our work. LDL-apheresis is
a speciﬁc type of EE, in which APOB becomes caught
in adsorbent columns together with compounds bound
to APOB. Our results revealed that there was only an
average of 0.28 ± 0.20nmol/L of atorvastatin in washing
liquids. Taking into account an average decrease of ator-
vastatin of 5.37nmol/L in serum after LDL-apheresis, the
retention of statins in washing liquids was less important.
It should be noted that washing liquids were examined
only for the ﬁrst cycle, although four cycles are typically
performed. The concentration of statins in washing liquids
after hemorheopheresis (on average, 3.04nmol/L) was found
to be higher than after LDL-apheresis, and the concentration
was 11.07nmol/L in the matrix of ﬁlters. The atorvastatin
in the serum decreased by an average of 18.08nmol/L
following hemorheopheresis. The amount of atorvastatin
retained in ﬁlters and washing liquids was therefore relatively
more important than after LDL-apheresis. The absolute
amount of retained statin following hemorheopheresis was
higher as compared with LDL-apheresis. This result is in
agreement with the nonspeciﬁcity of hemorheopheresis,
which is actually a ﬁltration procedure. The results can be
summarized in the following: even though the period with
lower levels of statins is not long (lasting only until the next
dose of statin) and although these levels are not clinically
dangerous (especially in LDL-apheresis), a certain amount
of statins is retained during EE, and it is convenient to take
a statin dose in the evening before EE (at least 15 hours
before EE), especially in the case of hemorheopheresis. EE
is then performed after the mean half-life elimination time
of statin; thus, the absolute loss of statin is lower. We have
shown (see above) that the absolute loss of statin is lower in
the patients taking a statin dose at least 15 hours before EE
than in patients taking the dose 2–4 hours before EE. It can
be hypothesized that the reason why statin losses decrease
with increasing the time interval between statin medication
and EE is simple—they are practically cleared in a longer
time after the mean life-time. Administration of medication
in the morning followed by EE at the time of maximum
statin plasma concentration is not ideal from this point of
view. Exceptional cases that require the patient to take the
drug in the morning on the day of EE can be resolved by the
recommendation to take the drug after EE.
5. Conclusion
The UHPLC-MS/MS analytical method developed for the
determination of statins present in biological materials
appears to be adequately sensitive, precise, and highly selec-
tive for the purpose of studying patients with FH after EE.
After EE, the concentrations of simvastatin and atorvastatin,
as well as their metabolites and interconversion forms, were
decreased. This outcome is conditioned by the decrease
in concentration over time (according to pharmacokinetic
properties), the type of procedure applied, and, most likely,
other factors as well. However, we observed speciﬁc levels
of statins in the washing liquids and ﬁlters. This amount
was more important after hemorheopheresis. Therefore, it is
convenient to prolong the interval between statin dosage and
EE to greater than the half-life of the statins (dose ∼6P . M .
the evening before the procedure). In contrast, a morning
dose of statins on the day of EE is inconvenient, especially
for hemorheopheresis.
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